retatrutide trial duration treatment clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Significantly Reduces Visceral Fat – Retatrutide Commercial Availability Timeline: Key

Evaluation for other etiologies (fibroids, polyps, thyroid dysfunction, perimenopause) is warranted

The trigger, though, is usually the nutritional shortfall created by rapid weight loss rather than the chemical itself

When you sleep well, your body can make more GLP-1, which helps with hunger control and metabolism

Supplement Guide: Boosting GLP-1 Naturally While diet and exercise lay the foundation, certain supplements can further support GLP-1 production

58 For all phase 2a, AEs were mild-moderate and GI-related, with no SAEs related to GSBR-1290

What the Data Shows The STEP 1 trial, published in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity to 2.4 mg weekly semaglutide or placebo for 68 weeks (1)